Medically reviewed by Drugs.com. Last updated on Mar 29, 2022.
Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether exenatide extended-release causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors has not been determined.Exenatide extended-release is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of exenatide extended-release and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for detection of MTC in patients treated with exenatide extended-release
Commonly used brand name(s)
In the U.S.
- Bydureon
- BYDUREON BCise
- Byetta
Available Dosage Forms:
- Solution
- Powder for Suspension, Extended Release
- Suspension, Extended Release
Therapeutic Class: Antidiabetic
Pharmacologic Class: Glucagon-Like Peptide-1 Receptor Agonist
Uses for exenatide
Exenatide injection is used together with diet and exercise to treat type 2 diabetes.
Exenatide is available only with your doctor's prescription.
Before using exenatide
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For exenatide, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to exenatide or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies ha..
